NCT00868803Active, not recruiting
Aberrant Gene Expression Prostate Carcinoma
Identification of Aberant Gene Expression in Human Prostatic Carcinoma
Source: ClinicalTrials.gov · Last updated 13 Jul 2026
Brief summary (registry, in English)
The goal of the study is to gain a better understanding of the molecular changes responsible for causing prostate cancer and that examination of tissue and blood samples will help in the development of improved screening and therapeutic approaches.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 5000 (estimated)
- First submitted
- 24 Mar 2009
- Start date
- Apr 1995
- Primary completion date
- Apr 2030
- Lead sponsor
- Lahey Clinic
- Diseases
- Prostate cancer, Childhood cancers
- NCT number
- NCT00868803
What you commit to
- Study type: Observational
- Planned participants: 5000
- From Apr 1995 to the primary completion date, Apr 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients not fitting the inclusion criteria
Who the study is looking for
- Diagnosed prostate cancer undergoing prostatectomy
- Suspicion of prostate cancer undergoing biopsy - negative biopsy
- Health volunteer (control group) - blood sample for PSA
Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lahey Clinic Coordinator of this site? Confirm its status | Burlington | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.